CHATHAM,N.J. – Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) announced that its Chief Executive Officer, Seth Lederman M.D., is scheduled to present at the Zacks SCR Life Sciences Virtual Investor Forum on Thursday, March 13, 2025, at 3:30 p.m. ET. This presentation offers investors an opportunity to learn more about the company’s strategic direction and development pipeline. The event aims to provide a comprehensive overview of tonix’s current operations, marketed products, and its diverse range of development candidates. The company is particularly focused on developing transformative therapies for pain management and innovative vaccines to address significant public health challenges.

The presentation by Dr. Lederman will delve into the specifics of Tonix Pharmaceuticals’ ongoing projects, highlighting key milestones and future goals. Investors will gain insights into the company’s approach to addressing unmet medical needs and its strategies for bringing novel treatments to market. The forum will also provide a platform for discussing the challenges and opportunities within the biopharmaceutical industry, particularly in the areas of pain management and infectious disease prevention.

Interested investors are encouraged to pre-register for the virtual presentation through VirtualInvestorConferences.com. This interactive online event will allow attendees to pose questions to the company in real-time, fostering a dynamic exchange of facts. The ability to engage directly with company leadership provides a valuable opportunity for investors to gain a deeper understanding of Tonix Pharmaceuticals’ vision and strategy.

For those unable to attend the live presentation, an archived webcast will be available on the Tonix website, accessible under the IR Events tab at www.tonixpharma.com. This ensures that all interested parties have access to the information shared during the forum, nonetheless of their ability to participate in the live event. The archived webcast will serve as a valuable resource for investors seeking to learn more about Tonix Pharmaceuticals and its future prospects.

tonix Pharmaceuticals emphasizes the importance of pre-registration and encourages online investors to run a system check prior to the event. This will help expedite participation and ensure attendees receive timely event updates. Additional details about the event can be found at www.virtualinvestorconferences.com.

Tonix Pharmaceuticals’ Focus

Tonix Pharmaceuticals is a fully-integrated biopharmaceutical company dedicated to developing innovative treatments. Their primary focus is on central nervous system (CNS) disorders,with a priority on advancing TNX-102 SL for fibromyalgia management. The Food and Drug Management (FDA) has assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for a decision on marketing authorization for TNX-102 SL.The FDA has also granted fast Track designation to TNX-102 SL for the management of fibromyalgia.

TNX-102 SL is also under development for treating acute stress reaction and acute stress disorder under a Physician-Initiated investigational New Drug (IND) submission at the University of north Carolina in the OASIS study, which is funded by the U.S. department of Defense (DoD).

The company’s CNS portfolio includes TNX-1300 (cocaine esterase), a biologic in Phase 2 development for treating cocaine intoxication. This program has received FDA Breakthrough Therapy designation and is supported by a grant from the National Institute on Drug Abuse.

Tonix’s immunology development portfolio includes TNX-1500,an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154).TNX-1500 is being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases and has completed a positive

Tonix Pharmaceuticals’ CEO Presentation: A Deep Dive into Pain Management and Vaccine Innovations

Is the biopharmaceutical industry on the cusp of a breakthrough in pain management and vaccine development? The answer may lie in the innovative approaches being pursued by companies like Tonix Pharmaceuticals.

Interviewer: Dr. Anya Sharma, welcome to World Today News. Your expertise in biopharmaceutical development and pain management is highly regarded. Tonix Pharmaceuticals CEO, Seth Lederman, is presenting at the Zacks Virtual Investor Forum. Could you give our readers a concise overview of Tonix’s current strategic direction and key areas of focus?

Dr. Sharma: Tonix Pharmaceuticals is a compelling example of a company pushing boundaries in biopharmaceutical innovation. Their strategic direction is clearly focused on developing transformative therapies for pain management and vaccines. This dual approach strategically addresses significant unmet medical needs in two crucial healthcare sectors. they’re not just tinkering at the edges; they are genuinely trying to reshape treatment landscapes. Their focus is multifaceted, including the development of novel therapies for fibromyalgia, acute stress reactions, and cocaine intoxication, as well as exploring innovative vaccine technologies.This diversified portfolio mitigates risk while targeting considerable market opportunities.

Interviewer: Let’s delve into Tonix’s most advanced candidate, TNX-102 SL for fibromyalgia. What makes this drug candidate so promising, and what are the potential implications of its success?

Dr. sharma: TNX-102 SL represents a significant advancement in the treatment of fibromyalgia, a chronic condition causing widespread pain and fatigue. Its novel mechanism of action offers a unique approach compared to existing treatments, perhaps addressing unmet needs in symptom management and improving quality of life for patients. The FDA’s fast-track designation and the assigned PDUFA date reflect the considerable promise the agency sees in this candidate. Successful marketing authorization for TNX-102 SL could transform current fibromyalgia treatment paradigms, making a tangible difference in the lives of millions of chronic pain sufferers. This translates to a substantial market opportunity and potential for significant revenue growth for Tonix. The key question of efficacy and longer-term safety remains to be fully answered upon the FDA approval.

Interviewer: Tonix is also involved in developing treatments for acute stress and cocaine intoxication. Could you elaborate on these projects and their potential impact?

Dr. sharma: The research on TNX-102 SL for managing acute stress reaction and acute stress disorder, especially the OASIS study, highlights Tonix’s commitment to addressing critical mental health challenges. This is a crucial area with a pressing need for safe and effective therapies. Moreover, their work on TNX-1300 for cocaine intoxication represents an innovative approach to a major public health problem. The FDA’s Breakthrough Therapy designation underscores the potential of TNX-1300 to fill a critical gap in the treatment of cocaine overdose and addiction. These developments are crucial not only for improving patient outcomes but also for advancing our understanding of these complex conditions.

Interviewer: Beyond pain management, Tonix is also developing vaccines. What is their strategy in this area, and what makes it unique?

Dr. Sharma: Tonix’s strategic approach to vaccine development is less publically available at this time, but the overall impact of pursuing both pain management and vaccines is excellent; they are demonstrating a commitment to public health in multiple areas. Developing vaccines for major diseases necessitates innovation, and success in this area would have enormous global health implications, aligning with Tonix’s commitment to innovative therapies addressing major unmet needs.Research on vaccine production is constantly evolving, and it will be valuable to examine what innovations Tonix brings to the table.

Interviewer: What are the major challenges and opportunities Tonix might face in the near future?

Dr. Sharma: The biopharmaceutical industry is highly competitive and inherently risky. Regulatory hurdles, clinical trial complexities, and competitive pressures are always inherent challenges. However, Tonix’s strategic diversification of potential markets helps mitigate overall risk. The sizable market opportunities within pain management and the ever-evolving dynamics of vaccine development present significant potential for growth. Successfully navigating the regulatory landscape and delivering positive clinical trial results will be central to Tonix’s future success. The ability to secure funding and partnerships will also play a significant role.

Interviewer: What is your overall assessment of Tonix Pharmaceuticals’ potential and its place within the evolving biopharmaceutical landscape?

Dr.Sharma: Tonix Pharmaceuticals holds a promising position within the biopharmaceutical landscape. Their targeted focus on addressing significant unmet needs in pain management and vaccine development, coupled with their innovative approach to therapeutic development, positions them favorably for future success. Their diverse pipeline, combined with their commitment to advancing unmet medical needs, make them an important player to watch.

Interviewer: Dr.Sharma, thank you for sharing your insightful perspective on Tonix Pharmaceuticals. This has been extremely helpful for our readers.

Dr. Sharma: My pleasure. I look forward to seeing the continued advancement of Tonix’s pipeline. Let’s see their accomplishments over the next few years.

Key Takeaways:

Tonix Pharmaceuticals focuses on developing transformative therapies for pain management and vaccines.

TNX-102 SL for fibromyalgia is a highly promising candidate with potential to change treatment standards.

Tonix’s diversified approach to treatment, including acute stress, cocaine intoxication, and vaccines, minimizes risk.

Navigating regulatory hurdles and securing funding will determine future success.

* The company’s dedication to innovative solutions positions them favorably in the biopharmaceutical sector.

Share your thoughts on Tonix Pharmaceuticals’ future in the comments below!